Petefészekrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• BRCA1 20
• BRCA2 13
• PARP 27
• TP53 6
• PD-1 12
• AKT 2
• HER2 16
• PD-L1 7
• PI3K 3
• STAT3 1
• mTOR 0
• VEGF 7
• KRAS 6
• EGFR 3
• PTEN 2
• MAPK 0
• CTNNB1 0
• FAK 1
• MYC 0
• NRF2 0
• CTLA-4 6
• ERK 1
• JAK 0
• STING 0
• GPX4 0
• HIF-1 0
• MEK 1
• TROP2 4
• PALB2 5
• B7-H3 7
• CDK4/6 4
• ATM 1
• CD47 0
• IL-6 0
• PIK3CA 3
• EZH2 1
• JNK 0
• YAP 0
• BCL-2 0
• BRAF 4
• CXCR4 0
• HDAC 0
• PPAR 0
• AMPK 0
• ARID1A 3
• AXL 1
• COX-2 2
• NMDA 0
• TIGIT 0
• AR 0
• CD40 1
• HER3 1
• HMGB1 0
• KEAP1 1
• METTL3 0
• RAS 0
• TLR4 0
• FGFR 0
• PINK1 0
• PKM2 0

28+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · F31

  The role of p16 expression in sensitivity and resistance to CDK2 inhibitors

  University of Colorado· Boulder, Egyesült Államok· 43 146 USD awarded in fiscal year 2026· until 2029. szept.

• NIH NIAID · R56

  Functional dissection of a novel E2 complex critical for the HPV16 life cycle

  Virginia Commonwealth University· Richmond, Egyesült Államok· 768 308 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NCI · R01

  Overcoming ovarian cancer chemoresistance by co-targeting senescence and apoptosis

  Harvard University D/B/A Harvard School of Public Health· Boston, Egyesült Államok· 390 447 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R01

  Immune Dysfunction, Social Determinants of Health, and Ovarian Cancer Outcome Differences

  University of Pittsburgh at Pittsburgh· Pittsburgh, Egyesült Államok· 674 142 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NICHD · R61

  Ultrasound-guided Ovarian Tissue Graft generation Platform to improve fertility outcomes

  Atera Medical· Mountain View, Egyesült Államok· 377 257 USD awarded in fiscal year 2026· until 2028. jún.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Decoding the Lipidome of Adipose-Derived Extracellular Vesicles in Ovarian Cancer: Mechanistic Insight into Tumor-Adipose Crosstalk (Lipid-Ex)

  Philipps Universitaet Marburg· Marburg, Németország· EU contribution 202 125 EUR· until 2028. dec.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Precision Reasoning In Multimodal Ovarian cancer (PRIMO)

  Institut Regional du Cancer de Montpellier· Montpellier Cedex 5, Franciaország· EU contribution 150 000 EUR· until 2028. jún.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  CAR T ceLls with Anti-exhaUstion Device for Immunotherapy Advancement (CLAUDIA)

  Fondazione Istituto Italiano di Tecnologia· Genova, Olaszország· EU contribution 150 000 EUR· until 2028. márc.

• European Commission (Horizon Europe) · HORIZON-EIC

  Interpretable Multimodal Predictive Agents and Digital Twins for Ovarian Cancer (IMPACT-OC)

  Danube Private University Gmbh· Krems-Stein, Ausztria· EU contribution 3 977 586 EUR· until 2030. szept.· 5 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  A Novel Phase-2a Clinical Trial for a Next-Generation Oncolytic Immunotherapy Targeting Platinum-Resistant Ovarian Cancer (OCTOPOD-Ph2a)

  Theolytics Ltd· Oxford, Egyesült Királyság· EU contribution 7 998 791 EUR· until 2029. máj.· 3 countries

10 of 669 running projects, newest first. Listed amounts together: 373,6 M USD + 54,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Felfüggesztve

  Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

  NCT04840589· National Cancer Institute (NCI)· Frissítve: 2026. nov. 12.

  “Other - Pending amendment.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  ITIL-306 in Advanced Solid Tumors

  NCT05397093· Instil Bio· Frissítve: 2026. ápr. 15.

  “The study was terminated early due to discontinuation of development of the investigational program”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.

  NCT06546553· Pfizer· Frissítve: 2026. febr. 23.

  “Study terminated as part of strategic considerations and not based on safety concerns.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

  NCT04260802· Ocellaris Pharma, Inc.· Frissítve: 2026. jan. 12.

  “Business Decision”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors

  NCT06285097· Pfizer· Frissítve: 2025. szept. 17.

  “The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

  NCT04042116· Clovis Oncology, Inc.· Frissítve: 2022. dec. 20.

  “Company decision”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

  NCT04840589· National Cancer Institute (NCI)· Forrás

• MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

  NCT05007106· Merck Sharp & Dohme LLC· Forrás

• Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

  NCT03740165· Merck Sharp & Dohme LLC· Forrás

• Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer

  NCT07591831· Tianjin Medical University Cancer Institute and Hospital· Forrás

• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

  NCT03797326· Merck Sharp & Dohme LLC· Forrás

• Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

  NCT05116189· Merck Sharp & Dohme LLC· Forrás

• INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

  NCT04580485· Incyte Corporation· Forrás

• A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

  NCT04042116· Clovis Oncology, Inc.· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 48
• Organoids 19
• Mendelian Randomization Analysis 30
• CRISPR-Cas Systems 15
• Gene Expression Profiling 126
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 6
• Exome Sequencing 11
• Proteomics 62
• Metabolomics 17
• Mass Spectrometry 6
• Flow Cytometry 26
• Immunohistochemistry 95
• Liquid Biopsy 15
• Circulating Tumor DNA 14
• Xenograft Model Antitumor Assays 234
• Positron-Emission Tomography 9
• Magnetic Resonance Imaging 57
• Machine Learning 60
• Deep Learning 36
• Cohort Studies 105
• Genome-Wide Association Study 27

• Si-scRNA-seq: Enabling ambient-stable single-cell transcriptomics through spatially confined biosilicification.

  Proc Natl Acad Sci U S A, 2026. okt.

• Combining network toxicology, single-cell RNA sequencing, and in vitro/in vivo experimental models reveals MMP9 as the key mediator of 27-hydroxycholesterol-driven ovarian cancer.

  Chem Biol Interact, 2026. aug.

• PCRD-seq: proximity crosslinking-induced RNA depletion sequencing for low-input chromatin-associated transcriptome profiling.

  Nucleic Acids Res, 2026. aug.

• Discovering reference-missing cell types in bulk transcriptomics.

  Bioinformatics, 2026. aug.

• Single-cell RNA sequencing in ovarian cancer: decoding the tumor microenvironment for personalized therapy.

  J Ovarian Res, 2026. jún.

• Identification of macrophage-enriched genes in ovarian cancer by single-cell RNA sequencing and establishment of a prognosis model.

  Sci Rep, 2026. jún.

• scMagnifier: Resolving fine-grained cell subtypes via GRN-informed perturbations and consensus clustering.

  PLoS Comput Biol, 2026. jún.

• Immune Landscape and Tumour Heterogeneity in Ovarian Cancer: Insights From Single-Cell RNA Sequencing.

  J Cell Mol Med, 2026. jún.

• Discovery of Anoikis-correlated Biomarkers for Ovarian Cancer Through Integrated Transcriptome and Single-cell RNA Sequencing Analyses.

  Curr Top Med Chem, 2026. jan.

• De Novo Detection of Clonal Structure and Evolution in Single-Cell and Spatial Transcriptomes.

  Int J Mol Sci, 2025. nov.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.